At ASCO 2020 meeting, the new final survival results of the SPARTAN study were reported. When we look at overall survival in SPARTAN, the use of apalutamideprolongs survival from 60 months to 74 months – that is a 14-month survival advantage, with a hazard ratioof 0.78. Earlier reports have shown significant advantages in reduction of ...

CheckMate 9LA is the second trial in a row of trials investigating the role of immunotherapy combinations in patients with non-small cell lung cancer (NSCLC). At the preplanned interim analysis after 8.1 months, overall survival was significantly prolonged with the combination of ipilimumab (IPI) and nivolumab (NIVO) and chemo vs chemo alone as front-line therapy in unselected patients with advanced ...

MEDtalk: Key takeways in prostate cancer from ASCO20 Virtual

ASCO20 Virtual | Best Practice Nordic | 12. Jun 2020 kl. 9:33 |

Watch the key takeaways in prostate cancer from ASCO20 Virtual by Professor Eric ...

Do patients with non-metastatic castration-resistant prostate cancer exist or do they all have metastases if submitted to a PET scan? See Eric J. Small’s MEDtalk and hear his thoughts on the ...

Professor Martin Reck explaining the background for CheckMate 9LA-study and the effect of the combination of nivolumab and ipilimumab + 2 cycles of chemotherapy as first-line treatment of stage IV/recurrent non-small cell lung ...

In this MEDtalk, Eric J. Small, MD and principal investigator of the SPARTAN study describes what characterizes the group of patients with non-metastatic castration-resistant prostate ...

In this MEDtalk, Eric J. Small, MD and principal investigator of the SPARTAN study, explains the clinical benefits from early treatment of patients with non-metastatic castration-resistant prostate ...

Non-small-cell lung cancer (NSCLC) stage III patients are inoperable and are offered chemotherapy or radiation therapy if the patient’s performance status allows it. However, no reduction in relapse is achieved, and the five-year survival rate of this treatment is low. The anti-PD-L1 checkpoint inhibitor pembrolizumab has shown long-term clinical efficacy as first-line treatment in metastatic ...

The 3 KEYNOTE-189 study has compared pembrolizumab, plus pemetrexed and platinum versus placebo plus pemetrexed-platinum as first-line therapy in patients with metastatic, non-squamous, non-small cell lung cancer without sensitizing EGFR of ALK mutation, regardless of PD-L1 aspiration. The final analysis of the study was presented at this year’s ASCO20 congress by Delvys Rodriguez-Abreu, medical oncologist ...

Osimertinib is a tyrosine kinase inhibitor that inhibits both activating EGFR mutations and the EGFR T790M resistance mutation. The question is whether osimertinib can be used at an earlier stage of the disease in a patient group, where the majority is getting progression and frequent central nervous system metastases. The ADAURA study has evaluated osimertinib ...

#Siste magasin

BestPractice Nordic

Nr. 2 • juni 2020
1. Årgang
  • Diabetes type 2 og hjertesykdom
  • Pneumokokkvaksinering
  • Prevensjon